anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A cell stimulating composition for use in treating wounds and infections and for stimulating the growth of healthy tissues is prepared by distributing therapeutically effective amounts of chlorophyll in a carrier and incorporating therein a material so that the pH of the composition is 6.0 to 8.5.  Preferably the composition should be buffered at this pH range.  Chlorophylls of 15 per cent purity, preferably 70-90 per cent or more, may be used and chlorophyll derivatives such as chlorophyllide a and b, iron and copper phaeophytin, phaeophytin a and b, phactochlorin e and g and copper and iron complexes thereof, phaeophorbide a and b, isochloraphyllin a and b, chlorophyllin a and b, also sodium and potassium salts of any of the foregoing which contain acid hydrogens. The compositions comprise fluid, viscuns or solid preparations, containing water-soluble or water-insoluble chlorophylls, the latter being preferred for the less fluid preparations such as ointments, salves and the like of oily or fatty nature.  Emulsions of chlorophyll or of chlorophyll dissolved in oil, may be prepared by the use of dispersing agents such as certain waxes, ursolic acid, glyceryl and glycol fatty acid esters, soaps such as sodium, magnesium, calcium and zinc oleates and alkali metal salts of sulphuric acid esters of long chain alcohols.  More viscous materials may have as base materials one or more vegetable oils such as cottonseed, olive, linseed, soyabean and eucalyptus oils, liquid paraffin, lanolin, lard, aquaphor (eucerin), petrolatum, monolene (propylene glycol stearate), cholesterols, stearic and palmitic acids and other higher and lower fatty acids, their alcohols and esters thereof such as glyceryl stearate, palonitate and oleate.  Fatty preparations containing varying amounts of water have as an essential constituent water absorbing materials such as lanolin and preferably, in addition, 5 to 10 per cent glycerine. Anhydrous preparations contain a buffering agent so that in contact with water or aqueous secretions during application to the body, the compositions will have the desired fat.  Ointment bases containing free fatty acids are first treated with aqueous alkali e.g. solutions of sodium or potassium hydroxide or carbonate to saponify the fatty acids and then adjusted to the desired pH.  Any therapeutically compatible non-irritant buffering agent may be used in these compositions e.g., a strong inorganic acid or base with an appropriate acetate, citrate, acid phosphate or phthalate, boric acid and sodium borate, and citrus pectin.  The examples describe, inter alia, aqueous and oily compositions for injection.
The intervention will contain two components: 1) a non-interruptive best practice advisory (BPA) in the Epic Storyboard and 2) a default suggested calculator tab in the MDCalc Connect app. Six clinical decision rules will be included: Canadian CT Head Rule, Canadian C-spine Rule, HEART Score, PERC Rule, Wells' PE Criteria and Wells' DVT Criteria. Predefined criteria based on chief complaint, patient age and vital signs will be used to determine when a decision rule may be relevant in a patient encounter. When a patient meets all of the predefined criteria, the intervention will be triggered.
Atherosclerosis (AS) management typically relies on therapeutic drug interventions, but these strategies typically have drawbacks, including poor site specificity, high systemic intake, and undesired side effects. The field of cell membrane camouflaged biomimetic nanomedicine offers the potential to address these challenges thanks to its ability to mimic the natural properties of cell membranes that enable enhanced biocompatibility, prolonged blood circulation, targeted drug delivery, and evasion of immune recognition, ultimately leading to improved therapeutic outcomes and reduced side effects. In this study, a novel biomimetic approach is developed to construct the M1 macrophage membrane-coated nanoprodrug (MM@CD-PBA-RVT) for AS management. The advanced MM@CD-PBA-RVT nanotherapeutics are proved to be effective in inhibiting macrophage phagocytosis and facilitating the cargo delivery to the activated endothelial cells of AS lesion both in vitro and in vivo. Over the 30-day period of nanotherapy, MM@CD-PBA-RVT is capable of significantly inhibiting the progression of AS, while also maintaining a favorable safety profile. In conclusion, the biomimetic MM@CD-PBA-RVT shows promise as feasible drug delivery systems for safe and effective anti-AS applications.
Acute ingestion of exogenous ketone supplements in the form of a (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (R-BD R-βHB) ketone monoester (KME) can attenuate declines in oxygen availability during hypoxic exposure and might impact cognitive performance at rest and in response to moderate-intensity exercise. In a single-blind randomized crossover design, 16 males performed assessments of cognitive performance before and during hypoxic exposure with moderate exercise [2 × 20 min weighted ruck (∼22 kg) at 3.2 km/h at 10% incline] in a normobaric altitude chamber (4572 m, 11.8% O2). The R-BD R-βHB KME (573 mg/kg) or a calorie- and taste-matched placebo (∼50 g maltodextrin) were co-ingested with 40 g of dextrose before exposure to hypoxia. The R-βHB concentrations were rapidly elevated and sustained (>3 mM; P < 0.001) by KME. The decline in oxygen saturation during hypoxic exposure was attenuated in KME conditions by 2.4%-4.2% (P < 0.05) compared with placebo. Outcomes of cognitive performance tasks, in the form of the Defense Automated Neurobehavioral Assessment (DANA) code substitution task, the Stroop color and word task, and a shooting simulation, did not differ between trials before and during hypoxic exposure. These data suggest that the acute exogenous ketosis induced by KME ingestion can attenuate declining blood oxygen saturation during acute hypoxic exposure both at rest and during moderate-intensity exercise, but this did not translate into differences in cognitive performance before or after exercise in the conditions investigated.
Thiamine (vitamin B1) is a water-soluble vitamin that plays a key role in aerobic glucose metabolism. Thiamine is a cofactor of pyruvate dehydrogenase (PDH), an enzyme that must be activated for entry into the Krebs Cycle for aerobic metabolism. PDH activity is reduced in thiamine deficient states, resulting in a shift in pyruvate metabolism to the anaerobic pathway. This leads to increased lactate production and acidosis. Thiamine loss in the urine, with consequent thiamine deficiency, is not uncommon in diabetes. The investigators' preliminary studies have found that thiamine deficiency in occurs in as many as 39% of patients with DKA, and that thiamine levels are inversely associated with lactate and acidosis. The investigator hypothesizes that treating DKA patients with intravenous thiamine will lead to faster resolution of acidosis and improved aerobic metabolism. The investigator's secondary hypothesis is that thiamine treatment will shorten stays in the ICU and hospital and lead to utilization of fewer hospital resources.

In this randomized, double-blind, placebo-controlled trial, patients admitted to the hospital with DKA who are enrolled in the study will be randomized to either intravenous thiamine (200mg in 0.9% saline) twice daily for two days or an identical volume of 0.9% saline on the same schedule. The investigator's primary outcome is change in bicarbonate over the 24 hours following enrollment, with measurements at 0, 6, 12, 18, 24 hours, using a linear mixed-effects model. Secondarily, patients will be stratified by Type I and Type II DM. Additionally, a pre-planned sub-analysis of thiamine deficient subjects will be performed.
The aim of the present study was to summarize the effectiveness of amino acid supplementation on muscle strength, muscle volume, and functional capacity in patients undergoing total knee arthroplasty. For this, in November 2022, a search was carried out in the PubMed, Cochrane Library, and EMBASE databases, identifying a total of 2182 documents, of which only 4 were included in the present review. The included studies had 148 participants (47 men and 101 women), with a minimum age of 53 and a maximum of 92 years, and supplementation times of 13 to 30 days (1 to 3 times a day). For the results, in relation to muscle performance, when comparing the control and experimental groups, greater muscle atrophy was observed in the pre- and post-moments of the control group, in relation to the experimental group. In addition, studies suggest a good tendency for muscle mass gain, and improvement in the functional capacities of patients who used supplementation. Therefore, the use of amino acids after TKA surgery reduces muscle atrophy, which preserves muscle mass and leads to better performance in tests of strength and functional capacity, when compared to the use of a placebo.
Infections after total ankle replacement (TAR) within the first 4 weeks after implantation can be managed successfully with 1 or several debridements, irrigation, and a change of polyethylene inlay. Late infections require implant removal. Low-grade infections might be an underestimated problem so far. Although single-surgery revisions are reported in the literature, the authors' experience with 2-stage revisions using an antibiotics-loaded bone cement spacer is better. Additional antibiotics are used to support the surgical treatment. After antibiotic therapy of 12 weeks, the final treatment includes ankle or tibio-talo-calcaneal fusion and, with limitations, revision TAR.
Bronchiolitis is common infection in the small airways of the lungs in the pediatric population. It typically affects children under the age of two years during the fall and winter months.Infants with this condition often have a significant amount of nasal drainage and congestion. Infants are known to be obligate nasal breathers. When the nasal secretions block the nasal airway, then breathing, sleeping, and eating/drinking all become very difficult. For this reason it is very important to have a good method of suctioning out the nose and clearing out the secretions. Historically a baby's nose was suctioned with a bulb syringe. These are still commonly used and are given out in the hospital setting, although there are many other types of devices that have been developed recently that are used for suctioning. One of these devices that has become very common among parents now is called the NoseFrida. It is important to evaluate this device and its efficacy compared to the bulb syringe.

This research study will evaluate the difference in effectiveness of nasal suction between two different suction devices (NoseFrida and bulb syringe) in infants that have bronchiolitis. Bronchiolitis (a virus infection that goes into the lungs, which subsequently causes difficulty breathing, difficulty sleeping, and difficulty eating and drinking in children) is a common infection in young children. Patients will be considered for enrollment in the study based on inclusion/exclusion criteria. The patient's caregiver will be supplied with an information sheet, and any questions will be addressed. Those who verbally consent will be enrolled in the study. After parents or guardians (caregivers) provide informed consent for their child, researchers will review the child's medical record for information regarding their history of respiratory distress. The caregiver will then be supplied with a suction device to be used once they are discharged home. The participants will be asked to use a NoseFrida device or a bulb syringe. The device supplied which is instructed to be used will be dependent on the week of enrollment in the study. Education will be given on how to use their respective the suction device devices. Along with the device, a form (Home monitoring form) will be supplied that will outline what should be monitored while using the device, including: number of days after discharge until respiratory symptoms resolve, number of days until the infant is eating/drinking well, and the number of days until the infant is sleeping well. A REDCAP survey will be emailed to participants after 5 days post discharge and again 7 days post discharge if not completed.

The protocol was revised to supply both nasal suction devices to the participants. However, no data was collected under this revised protocol before termination.
BACKGROUND: The role of insulin resistance in hepatic fibrosis in Metabolic dysfunction-Associated SteatoHepatitis (MASH) remains unclear. Carcinoembryonic Antigen-related Cell Adhesion Molecule1 protein (CEACAM1) promotes insulin clearance to maintain insulin sensitivity and repress de novo lipogenesis, as bolstered by the development of insulin resistance and steatohepatitis in AlbuminCre + Cc1fl/fl mice with liver-specific mouse gene encoding CEACAM1 protein (Ceacam1) deletion. We herein investigated whether these mice also developed hepatic fibrosis and whether hepatic CEACAM1 is reduced in patients with MASH at different fibrosis stages.
METHODS: AlbuminCre + Cc1fl/fl mice were fed a regular or a high-fat diet before their insulin metabolism and action were assessed during IPGTT, and their livers excised for histochemical, immunohistochemical and Western blot analysis. Sirius red staining was used to assess fibrosis, and media transfer was employed to examine whether mutant hepatocytes activated hepatic stellate cells (HSCs). Hepatic CEACAM1 protein levels in patients with varying disease stages were assessed by ELISA.
RESULTS: Hepatocytic deletion of Ceacam1 caused hyperinsulinemia-driven insulin resistance emanating from reduced hepatic insulin clearance. AlbuminCre + Cc1fl/fl livers showed inflammation, fibrosis and hepatic injury, with more advanced bridging and chicken-wire hepatic fibrosis under high-fat conditions. Media transferred from hepatocytes isolated from mutant mice activated control HSCs, likely owing to their elevated endothelin1 content. Interestingly, hepatic CEACAM1 levels were lower in the livers of patients with MASH and declined gradually with advanced fibrosis stage.
CONCLUSIONS: Hepatic CEACAM1 levels declined with progression of MASH in humans. The phenotype of AlbuminCre + Cc1fl/fl mice assigned a key role to CEACAM1 loss from hepatocytes in hepatic fibrosis independently of other liver cells.
A method for topical treatment of rosacea comprising application of a formulation to the affected area is disclosed. The formulation comprises one or more iron chelators. Omadine, a bispyrithione salt, and kojic acid are the preferred iron chelators. The formulation also comprises one or more false substrates for arachidonic acid. The preferred false substrates for arachidonic acid are alpha-linoleic acid and gamma dihomo-linolenic acid. The formulation further comprises an inhibitor of stratum corneum tryptic enzyme (SCTE). A preferred stratum corneum tryptic enzyme inhibitor is zinc. The formulation also preferably includes one or more medium-chain saturated fatty acid monoester. The preferred medium-chain fatty acid monoesters are glycerol monolaurate and glycerol monocaprylate. Formulation components are solubilized in a suitable carrier base which includes emollient, humectant, antioxidant and sunscreen components. The method preferably comprises application of a leave-on formulation. Alternatively, a pre-step of application of a rinse-off formulation containing a higher concentration of an iron chelator may be employed in the regimen.
The invention relates to a medicine for treating AOFH (alcohol-induced osteonecrosis of femoral head). The medicine is prepared from raw materials in parts by weight as follows: 8 parts of thinleaf milkwort root-bark, 3 parts of lotus leaves, 6 parts of golden thread, 8 parts of eucommia bark, 8 parts of twotooth achyranthes roots, 6 parts of beehives, 9 parts of Indian quassiawood twigs and leaves, 6 parts of lygodii spora, 6 parts of safflower and 8 parts of radix hedysari. The thinleaf milkwort root-bark has the efficacy of tranquilizing the mind and promoting the intelligence; the lotus leaves have the efficacy of sending up the lucid yang; the golden thread has the efficacy of purging fire and removing toxin; the eucommia bark and the twotooth achyranthes roots have the efficacy of tonifying liver and kidney, strengthening muscle and bone, removing stasis and dredging meridians; the beehives have the efficacy of dispelling wind and relieving pains; the Indian quassiawood twigs and leaves have the efficacy of clearing heat, dispelling dampness and removing toxin; the lygodii spora has the efficacy of clearing dampness and heat, treating stranguria and relieving pains; the safflower has the efficacy of activating blood circulation and dispelling stasis; the radix hedysari has the efficacy of removing toxin and promoting tissue regeneration. The medicinal raw materials are used together and have the functions of tranquilizing the mind, promoting the intelligence, tonifying the liver and the kidney, strengthening muscles and bones, dispelling wind, relieving pains, dispelling dampness and removing toxin. The medicine achieves the purpose of treating AOFH. Clinical experiments prove that the medicine can treat AOFH safely and effectively.
The two-tier human subjects study will be conducted to assess the biomechanical characteristics of PAS. In the first tier, we will test PAS in healthy subjects and in the second tier, we will test PAS in Diabetic Neuropathy patients (DN).

Subjects will walk on a treadmill in their usual daily shoes for 5 minutes, then with standard diabetic shoes with the PAS insoles for 5 minutes. Subjects will wear body worn sensors that assess position of the body. Subjects will have the temperature of their feet measured via a special camera after walking. Subjects will rest for 30 minute washout period and have the blood flow in the soles of the feet measured via a special camera. 1 healthy subject will undergo MRI of the foot and ankle.
In the intraoperative and postoperative settings it is not always advisable to slowly titrate the dose of esmolol hydrochloride to a therapeutic effect. Therefore, two dosing options are presented: immediate control dosing and a gradual control when the physician has time to titrate.

  1. Immediate Control   
For intraoperative treatment of tachycardia and/or hypertension give an 80 mg (approximately 1 mg/kg) bolus dose over 30 seconds followed by a 150 mcg/kg/min infusion, if necessary. Adjust the infusion rate as required up to 300 mcg/kg/min to maintain desired heart rate and/or blood pressure.
  2. Gradual Control   
For postoperative tachycardia and hypertension, the dosing schedule is the same as that used in supraventricular tachycardia. To initiate treatment, administer a loading dosage infusion of 500 mcg/kg/min of esmolol hydrochloride for one minute followed by a four-minute maintenance infusion of 50 mcg/kg/min. If an adequate therapeutic effect is not observed within five minutes, repeat the same loading dosage and follow with a maintenance infusion increased to 100 mcg/kg/min (see above SUPRAVENTRICULAR TACHYCARDIA).  




Notes:

1\. Higher dosages (250-300 mcg/kg/min) may be required for adequate control of blood pressure than those required for the treatment of atrial fibrillation, flutter and sinus tachycardia. One third of the postoperative hypertensive patients required these higher doses.

2\. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
The invention discloses a traditional Chinese medicine composition for treating dysmenorrhea. The traditional Chinese medicine composition comprises 20g of corydalis yanhusuo, 15g of safflower, 5g of largehead atractylodes rhizome, 6g of pinellia ternate, 3g of common monkshood mother root and 25g of cinnamon. Corydalis yanhusuo has the effect of regulating qi to alleviate pain. Safflower has the effect of activating blood to promote menstruation. Largehead atractylodes rhizome has effects of invigorating spleen and supplementing qi. Pinellia ternate has effects of dissolving lumps and resolving masses. Common monkshood mother root has the effect of warming the channels to relieve pain. Cinnamon has the effect of activating blood to promote menstruation.
PURPOSE:To provide a carcinostatic agent containing a specific platinum complex as an active component. CONSTITUTION:A compound of formula 1 (A is direct bond or -CH2-), e.g. cis- dichloro-trans-dihydroxo[1-(2-aminoethyl)pyrrolidine]platinum (IV) is used as an active component of the objective agent. The agent is administered in the form of an oral drug such as a solid preparation (e.g. tablet, pill, capsule, etc.) or liquid preparation (e.g. solution, suspension, etc.) or a parenteral drug such as injection, suppository, etc., at a dose of 200-400mg/kg daily for oral drug and 100-200mg/kg daily for parenteral drug. The compound of formula 1 used as an active component can be produced by reacting the compound of formula 2 with the compound of formula 3 in an aqueous solvent at 0-100 deg.C for 1hr-4 days and reacting the resultant compound of formula 4 with hydrogen peroxide in an aqueous solvent at 0-120 deg.C for 30min-5hr. EFFECT:It has excellent anti-tumor activity and definitely weak bonding power to plasma protein compared with conventional platinum complex and CDDP, etc., and is useful as a carcinostatic agent.
After obtaining informed, written consent, candidates were randomized to one of four groups at the time of request for labor analgesia. All subjects received a maintenance infusion of Lactated Ringers(LR). For candidates in Groups A or B, an intravenous bolus of 1000 mL of LR was initiated. Candidates in Groups C and D did not receive any additional fluid. If randomized to group A or C, the oxytocin management was continued as per the normal active management of labor protocal (AMOL). If randomized to groups B or D, the dose of oxytocin that was being administered was halved and not increased until 60 minutes after the initiation of epidural analgesia. Fetal heart rate monitoring and frequency of uterine contractions were recorded by external tocodynamometry.
The recommended starting dosage of NEUPOGEN is 5 mcg/kg/day‚ administered as a single daily injection by subcutaneous injection‚ by short intravenous infusion (15 to 30 minutes)‚ or by continuous intravenous infusion. Obtain a complete blood count (CBC) and platelet count before instituting NEUPOGEN therapy and monitor twice weekly during therapy. Consider dose escalation in increments of 5 mcg/kg for each chemotherapy cycle‚ according to the duration and severity of the absolute neutrophil count (ANC) nadir. Recommend stopping NEUPOGEN if the ANC increases beyond 10‚000/mm3 [see Warnings and Precautions (5.10)].

Administer NEUPOGEN at least 24 hours after cytotoxic chemotherapy. Do not administer NEUPOGEN within the 24-hour period prior to chemotherapy [see Warnings and Precautions (5.13)]. A transient increase in neutrophil count is typically seen 1 to 2 days after initiation of NEUPOGEN therapy.

Therefore, to ensure a sustained therapeutic response‚ administer NEUPOGEN daily for up to 2 weeks or until the ANC has reached 10‚000/mm3 following the expected chemotherapy-induced neutrophil nadir. The duration of NEUPOGEN therapy needed to attenuate chemotherapy-induced neutropenia may be dependent on the myelosuppressive potential of the chemotherapy regimen employed.
A series of structurally diverse chemical and pharmaceutical compounds show antimicrobial activity. This new class of broad spectrum antimicrobials has been identified with molecular weight below 2600, high aqueous solubility, low cytotoxicity to mammalian cells and usefulness as preservatives, antibacterial, antifungal and food additive applications. - GIGTLLGKKKTKFLKNILKL as represented in -  ID sequence No. 1 -  - VGSLVGKRILSELRNLI as represented in -  ID sequence No. 2 -  as set fourth in SEQ. I.D. No. 1, or salts thereof.